Delhi high court orders injunction against Aarti Pharmalabs over patent infringement

Aarti Pharmalabs Limited announced on October 8, 2025, that it has received an ex-parte ad-interim injunction order from the High Court of Delhi. The order restrains the company from manufacturing, stockpiling, exporting, offering for sale, and/or supplying pharmaceutical drug products containing Ruxolitinib and/or Ruxolitinib Phosphate API, or any other formulation that would infringe Suit Patent No. IN269841. This alleged infringement relates to "Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines and Pyrrolo [2,3-B] Pyrimidines as Janus Kinase Inhibitors."

Following the injunction, a local commissioner and their team visited the company's office to inspect and collect relevant copies of ledgers and stock registers. Aarti Pharmalabs stated it fully cooperated with the officials, providing all requested clarifications and details.

The company confirmed that its business operations continued as usual and were not impacted by the search. Despite the legal action, Aarti Pharmalabs currently anticipates no financial impact from the injunction.